Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CVRx (CVRX)
NASDAQ:CVRX
Earnings Data
Report Date
Apr 23, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.54Last Year’s EPS
-1.04Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 04, 2025
|% Change Since: -10.71%
|Next Earnings Date:Apr 23, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and successful expansion in the U.S. market, alongside key reimbursement milestones and educational initiatives. However, challenges were noted in the European market, and there were increased operating expenses and interest expenses leading to a higher net loss.Company Guidance
During the CVRx Fourth Quarter 2024 Earnings Call, the company provided financial guidance for 2025, projecting total revenue between $63 million and $65 million and a gross margin of 83% to 84%. Operating expenses are expected to range from $100 million to $104 million. For the first quarter of 2025, the company anticipates revenue between $14.5 million and $15 million. In 2024, CVRx achieved a revenue growth of 36% over the previous year's fourth quarter, driven by a 41% increase in U.S. Heart Failure revenue. The company is focusing on building a sustainable Barostim program in target centers, optimizing reimbursement strategies, and expanding clinical evidence to support adoption. Key changes include transitioning to Category 1 CPT codes by January 2026, which will enhance prior authorization processes and expand market access.Strong Revenue Growth
CVRx reported total revenue of $15.3 million for Q4 2024, representing a growth of 36% over the fourth quarter of 2023. U.S. Heart Failure revenue grew by 41%.
Expansion and Market Penetration
The company expanded to 48 territories in the United States, ending the year with 223 active and planning centers, up from 178 at the end of 2023.
Reimbursement Milestones
CMS maintained Barostim in the new technology APC 1580 for 2025, preserving the reimbursement level of approximately $45,000 for outpatient procedures. Inpatient payment increased from $23,000 to approximately $43,000.
New Category 1 CPT Codes
The American Medical Association accepted new Category 1 CPT codes for Barostim therapy, expected to be implemented on January 1, 2026, which will improve prior authorization throughput.
Clinical Evidence and Education Initiatives
CVRx expanded educational programs and published a long-term post-COVID data set showing a five-fold decrease in hospitalization one year after Barostim therapy.
---
CVRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CVRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 04, 2025 | $16.25 | $15.08 | -7.20% |
| Oct 29, 2024 | $10.74 | $14.07 | +31.01% |
| Jul 29, 2024 | $9.27 | $7.92 | -14.56% |
| Apr 30, 2024 | $15.51 | $10.12 | -34.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does CVRx (CVRX) report earnings?
CVRx (CVRX) is schdueled to report earning on Apr 23, 2025, TBA Not Confirmed.
What is CVRx (CVRX) earnings time?
CVRx (CVRX) earnings time is at Apr 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CVRX EPS forecast?
CVRX EPS forecast for the fiscal quarter 2025 (Q1) is -0.54.
---